Pay in 4 interest-free payments of $5.84 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Zepbound (tirzepatide for obesity) launched November 2023 and went into shortage within weeks due to overwhelming demand
oral formulation (Rybelsus) also available Lixisenatide (Lyxumia) once-daily injection NICE guidance for type 2 diabetes (NG28) recommends GLP-1 receptor agonists in specific circumstances: typically as a third-line option when other treatments haven't achieved adequate glycaemic control, particularly in people with a BMI 35 kg/m (adjusted for ethnicity), or for whom weight loss would benefit other obesity-related comorbidities, or for whom insulin would have significant occupational implications
Providing patients with the knowledge and tools to monitor their health empowers them to participate actively in managing potential interactions
doi:10.1155/2016/6757154 20
Brand Zepbound is currently cheaper than brand Wegovy
Tirzepatide targets both the GLP-1 receptor as well as that of the GIP, which gives it a metabolic boosting factor that creates a better modality and efficiency for cell energy production
